CN102272148A - 抑制vegf-a受体相互作用的结合蛋白 - Google Patents

抑制vegf-a受体相互作用的结合蛋白 Download PDF

Info

Publication number
CN102272148A
CN102272148A CN2009801536047A CN200980153604A CN102272148A CN 102272148 A CN102272148 A CN 102272148A CN 2009801536047 A CN2009801536047 A CN 2009801536047A CN 200980153604 A CN200980153604 A CN 200980153604A CN 102272148 A CN102272148 A CN 102272148A
Authority
CN
China
Prior art keywords
leu
ala
acid residue
asp
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801536047A
Other languages
English (en)
Chinese (zh)
Inventor
H.K.宾茨
P.福雷尔
M.T.施图姆普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Priority to CN201710092752.9A priority Critical patent/CN107011425B/zh
Publication of CN102272148A publication Critical patent/CN102272148A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801536047A 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白 Pending CN102272148A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710092752.9A CN107011425B (zh) 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166 2008-11-03
EP08168166.0 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710092752.9A Division CN107011425B (zh) 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白

Publications (1)

Publication Number Publication Date
CN102272148A true CN102272148A (zh) 2011-12-07

Family

ID=40149742

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801536047A Pending CN102272148A (zh) 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白
CN201710092752.9A Active CN107011425B (zh) 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710092752.9A Active CN107011425B (zh) 2008-11-03 2009-11-03 抑制vegf-a受体相互作用的结合蛋白

Country Status (15)

Country Link
US (2) US8901076B2 (enExample)
EP (2) EP3785735A1 (enExample)
JP (2) JP5954990B2 (enExample)
KR (1) KR101698362B1 (enExample)
CN (2) CN102272148A (enExample)
AU (1) AU2009319204B2 (enExample)
BR (1) BRPI0921469B1 (enExample)
CA (1) CA2742241C (enExample)
DK (1) DK2358746T3 (enExample)
ES (1) ES2836948T3 (enExample)
IL (1) IL212589A (enExample)
MX (2) MX2011004649A (enExample)
NZ (1) NZ592591A (enExample)
RU (2) RU2550258C2 (enExample)
WO (1) WO2010060748A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002920A (zh) * 2010-04-30 2013-03-27 分子组合公司 抑制vegf-a受体相互作用的修饰结合蛋白
CN105338995A (zh) * 2013-04-22 2016-02-17 艾菲洛吉克公司 包含pli-ob变体的局部组合物
CN110845618A (zh) * 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
US9221892B2 (en) 2010-11-26 2015-12-29 Molecular Partners Ag Capping modules for designed ankyrin repeat proteins
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
JP6321545B2 (ja) 2011-11-16 2018-05-09 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
ES2707878T3 (es) 2011-11-16 2019-04-05 Adrenomed Ag Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para regular el equilibrio de líquidos en un paciente que presenta una enfermedad crónica o aguda
RS55804B1 (sr) 2011-11-16 2017-08-31 Sphingotec Gmbh Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina
PL2780370T3 (pl) 2011-11-16 2020-01-31 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta
PL2594587T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry
ES2729710T3 (es) 2011-11-16 2019-11-05 Adrenomed Ag Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
US10568934B2 (en) * 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
PT3858405T (pt) 2012-06-01 2023-06-26 Novartis Ag Seringa
RU2014150224A (ru) 2012-06-28 2016-08-20 Молекьюлар Партнерс Аг Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
WO2014033184A1 (en) * 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
RU2679913C2 (ru) 2012-10-02 2019-02-14 Сфинготек Гмбх Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN104937421B (zh) 2013-01-08 2018-01-19 斯弗因高泰克有限公司 生长激素的禁食水平作为心血管风险的预测标志物
RU2720412C2 (ru) * 2013-03-14 2020-04-29 Аллерган, Инк. Композиции доставки с замедленным высвобождением и способ стабилизации белков в процессе изготовления
EP2976646B1 (en) 2013-03-20 2020-08-19 sphingotec GmbH Adrenomedullin to guide therapy of blood pressure decline
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
US20160129080A1 (en) 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
CN105377891A (zh) 2013-07-11 2016-03-02 诺华股份有限公司 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
US20160159893A1 (en) 2013-07-11 2016-06-09 Gabriela Burian Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
US20160097781A1 (en) 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
RU2769470C2 (ru) * 2015-04-02 2022-04-01 Молекьюлар Партнерс Аг Рекомбинантные связывающие белки и их применение
CA2983542A1 (en) 2015-04-24 2016-10-27 Sphingotec Gmbh A method for predicting the risk of incidence of chronic kidney disease
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
EP4556023A3 (en) 2015-11-18 2025-10-15 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
WO2017148904A1 (en) 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
CN120093910A (zh) 2016-04-21 2025-06-06 怡双富制药有限公司 Dpp3活性抑制剂、包含其的药物组合物及其用途
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
RU2019103403A (ru) 2016-07-08 2020-08-10 Сфинготек Гмбх Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
US20200299372A1 (en) 2016-12-16 2020-09-24 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
MX2019014441A (es) 2017-05-30 2020-02-10 Sphingotec Gmbh Un metodo in vitro para diagnosticar o monitorear la funcion renal o diagnosticar disfuncion renal.
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019034332A1 (en) 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS
CN119215164A (zh) 2017-09-25 2024-12-31 艾德里诺医药公司 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂
CN111480076A (zh) 2017-10-18 2020-07-31 艾德里诺医药公司 抗肾上腺髓质素（adm）结合剂治疗下的疗法监测
SG11202002391PA (en) 2017-10-24 2020-04-29 Sphingotec Gmbh Selenoprotein p for prediction of a first cardiovascular event
AU2018356441B2 (en) 2017-10-25 2024-12-19 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
WO2019154900A1 (en) 2018-02-08 2019-08-15 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
CA3124020A1 (en) 2018-12-20 2020-06-25 Sphingotec Gmbh Selenoprotein p in heart failure
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
CA3146885A1 (en) 2019-08-15 2021-02-18 Andreas Bergmann A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
CA3148275A1 (en) 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
CN115003689A (zh) 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
EP4111204A1 (en) 2020-02-27 2023-01-04 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
MX2022010207A (es) 2020-02-27 2022-11-16 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.
CN115244081A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
BR112022017890A2 (pt) 2020-03-16 2022-11-01 Sphingotec Gmbh Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina
JP2023518731A (ja) 2020-03-16 2023-05-08 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング コロナウイルスに感染した患者におけるｄｐｐ３
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
EP4304731A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based multi-specific t-cell engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
EP4356139A1 (en) 2021-06-18 2024-04-24 sphingotec GmbH A method for predicting sepsis and septic shock
KR20240041912A (ko) 2021-06-29 2024-04-01 베리솔 게엠베하 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
AU2022413461A1 (en) 2021-12-14 2024-06-06 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
AU2023233838A1 (en) 2022-03-15 2024-09-26 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
IL318514A (en) 2022-08-01 2025-03-01 Molecular Partners Ag Loading and using modified re-designed websites
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
CN120731367A (zh) 2023-03-17 2025-09-30 Pam治疗诊断有限公司 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途
CN120857945A (zh) 2023-03-29 2025-10-28 4Teen4制药有限公司 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂
WO2025068313A1 (en) 2023-09-25 2025-04-03 Sphingotec Gmbh A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816566A (zh) * 2003-06-30 2006-08-09 瑞泽恩制药公司 Vegf捕获剂及其治疗用途
CN101141975A (zh) * 2005-03-25 2008-03-12 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2008094969A2 (en) * 2007-02-01 2008-08-07 Genentech, Inc. Combination therapy with angiogenesis inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
ES2280131T3 (es) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. Fusiones de adn-proteina y utilizaciones de las mismas.
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20060129246A (ko) * 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
NZ581958A (en) * 2004-11-12 2011-01-28 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer
AU2006268780B2 (en) 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816566A (zh) * 2003-06-30 2006-08-09 瑞泽恩制药公司 Vegf捕获剂及其治疗用途
CN101141975A (zh) * 2005-03-25 2008-03-12 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2008094969A2 (en) * 2007-02-01 2008-08-07 Genentech, Inc. Combination therapy with angiogenesis inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NG. YS ET AL.: "VEGF function in vascular pathogenesis", 《EXPERIMENTAL CELL RESEARCH》 *
陈珊等: "血管内皮生长因子家族及其受体与肿瘤血管生成研究进展", 《生命科学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002920A (zh) * 2010-04-30 2013-03-27 分子组合公司 抑制vegf-a受体相互作用的修饰结合蛋白
CN103002920B (zh) * 2010-04-30 2018-03-02 分子组合公司 抑制vegf‑a受体相互作用的修饰结合蛋白
CN110845618A (zh) * 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
CN105338995A (zh) * 2013-04-22 2016-02-17 艾菲洛吉克公司 包含pli-ob变体的局部组合物

Also Published As

Publication number Publication date
MX2011004649A (es) 2011-05-30
JP6329503B2 (ja) 2018-05-23
CA2742241A1 (en) 2010-06-03
CN107011425B (zh) 2021-01-01
ES2836948T3 (es) 2021-06-28
US20110207668A1 (en) 2011-08-25
DK2358746T3 (da) 2020-12-21
AU2009319204B2 (en) 2014-11-13
AU2009319204A1 (en) 2010-06-03
EP3785735A1 (en) 2021-03-03
WO2010060748A1 (en) 2010-06-03
BRPI0921469B1 (pt) 2022-01-18
IL212589A (en) 2017-01-31
NZ592591A (en) 2012-04-27
IL212589A0 (en) 2011-07-31
KR101698362B1 (ko) 2017-01-20
JP5954990B2 (ja) 2016-07-20
BRPI0921469A2 (pt) 2016-01-12
KR20110082528A (ko) 2011-07-19
RU2011122201A (ru) 2012-12-10
CN107011425A (zh) 2017-08-04
US20150344539A1 (en) 2015-12-03
EP2358746A1 (en) 2011-08-24
JP2012507271A (ja) 2012-03-29
CA2742241C (en) 2019-12-10
MX359570B (es) 2018-10-01
US8901076B2 (en) 2014-12-02
EP2358746B1 (en) 2020-09-16
RU2550258C2 (ru) 2015-05-10
RU2650765C1 (ru) 2018-04-17
JP2015133978A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
US10646542B2 (en) Modified binding proteins inhibiting the VEGF-A receptor interaction
JP6329503B2 (ja) Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
HK1238258B (zh) 抑制vegf-a受体相互作用的结合蛋白
HK1238258A1 (en) Binding proteins inhibiting the vegf-a receptor interaction
HK1161726A (en) Binding proteins inhibiting the vegf-a receptor interaction
HK1179876B (en) Modified binding proteins inhibiting the vegf-a receptor interaction
HK1179876A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
AU2014243418A1 (en) Modified binding proteins inhibiting the VEGF-A receptor interaction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161726

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111207

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1161726

Country of ref document: HK